RxDoctor Payments Data

Thomas Winston, MD

Family Medicine · Amarillo, TXNPI 1083624308

Payments from drug & device makers

$570in general payments, 2019–2025

Across 15 payments — averaging $38.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Revance Therapeutics, Inc.$205
  • AstraZeneca$125
  • GSK$107
  • AbbVie$69
  • Merz North America, Inc.$30
  • Almatica Pharma LLC$22
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$570 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$111,381
Medicare patients
237
Services billed
1,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide167$178,061
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$56,693
FarxigaDapagliflozin Propanediol59$56,578
EliquisApixaban54$55,910
MounjaroTirzepatide49$52,864
JardianceEmpagliflozin28$34,729
Tresiba Flextouch U-200Insulin Degludec28$23,619
OxycontinOxycodone Hcl13$15,601
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$14,844
Xigduo XrDapaglifloz Propaned/Metformin13$10,178
EntrestoSacubitril/Valsartan13$10,042
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$8,039
XareltoRivaroxaban12$6,695
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,589
JanuviaSitagliptin Phosphate12$6,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$125$63,16770 claims
GSKTrelegy Ellipta$107$56,69389 claims
Johnson & JohnsonXarelto$12$6,69512 claims
AbbVieSynthroid$69$1,85629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →